<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848183</url>
  </required_header>
  <id_info>
    <org_study_id>2015-11-028</org_study_id>
    <nct_id>NCT02848183</nct_id>
  </id_info>
  <brief_title>Optimal Treatment Strategy Based on for Pediatric AML</brief_title>
  <official_title>Optimal Treatment Strategy Based on Prognostic Groups for Pediatric de Novo Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to optimize therapy according to the known risk factors and&#xD;
      treatment response in pediatric acute myeloid leukemia (AML)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      I. Risk group assessment Favorable prognosis group: Low risk features + Good response&#xD;
&#xD;
      Intermediate prognosis group:&#xD;
&#xD;
        1. Low risk features + Delayed response-1&#xD;
&#xD;
        2. Standard risk features + Good response&#xD;
&#xD;
        3. Standard risk features + Delayed response-1&#xD;
&#xD;
      Poor prognosis group:&#xD;
&#xD;
        1. Any high risk features irrespective of treatment response&#xD;
&#xD;
        2. Any delayed response-2 irrespective of risk features&#xD;
&#xD;
        3. Any refractory state irrespective of risk features&#xD;
&#xD;
        4. Any early relapse&#xD;
&#xD;
      II. Chemotherapy Induction-1: Cytarabine + idarubicin Induction-2: High dose (HD) cytarabine&#xD;
      + mitoxantrone Consolidation-1: Cytarabine + idarubicin Consolidation-2: HD cytarabine +&#xD;
      etoposide Consolidation-3: HD cytarabine + mitoxantrone Consolidation-4: HD cytarabine +&#xD;
      etoposide&#xD;
&#xD;
      III. Allogeneic hematopoietic stem cell transplantation (HSCT) Favorable prognosis group:&#xD;
      chemotherapy only Intermediate prognosis group: chemotherapy or HSCT with reduced intensity&#xD;
      conditioning Poor prognosis group: HSCT with myeloablative conditioning&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of event free survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieved complete remission</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment>350</enrollment>
  <condition>Pediatric Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Pediatric de novo acute myeloid leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>I. Chemotherapy Induction-1: Cytarabine + idarubicin Induction-2: High dose (HD) cytarabine + mitoxantrone Consolidation-1: Cytarabine + idarubicin Consolidation-2: HD cytarabine + etoposide Consolidation-3: HD cytarabine + mitoxantrone Consolidation-4: HD cytarabine + etoposide&#xD;
II. Allogeneic hematopoietic stem cell transplantation (HSCT) Favorable prognosis group: chemotherapy only Intermediate prognosis group: chemotherapy or HSCT with reduced intensity conditioning Poor prognosis group: HSCT with myeloablative conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Pediatric de novo acute myeloid leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <arm_group_label>Pediatric de novo acute myeloid leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <arm_group_label>Pediatric de novo acute myeloid leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>Pediatric de novo acute myeloid leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>Pediatric de novo acute myeloid leukemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who were newly diagnosed with de novo AML&#xD;
&#xD;
          -  Patients who had recurrent cytogenetic abnormalities of AML even though the bone&#xD;
             marrow blast percent is lower than 20%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia&#xD;
&#xD;
          -  Down syndrome AML&#xD;
&#xD;
          -  Therapy-related AML&#xD;
&#xD;
          -  AML developed from myelodysplastic syndrome or other marrow failure syndrome&#xD;
&#xD;
          -  Isolated myeloid sarcoma without bone marrow involvement&#xD;
&#xD;
          -  Patients who cannot undergo chemotherapy as scheduled due to serious complications at&#xD;
             diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Keon Hee Yoo, MD, PhD</last_name>
    <phone>82-2-3410-3532</phone>
    <email>hema2170@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Chonnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoon Kook, MD, PhD</last_name>
      <email>hoonkook@chonnam.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keon Hee, MD, PhD</last_name>
      <phone>82-2-3410-3532</phone>
      <email>hema2170@skku.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Cho, MD, PhD</last_name>
      <email>chobinkr@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

